Fig. 1: Prognostic impact of ultra-high-sensitivity next-generation sequencing–based measurable residual disease (UHS-NGS MRD) in older patients with acute myeloid leukemia. | Blood Cancer Journal

Fig. 1: Prognostic impact of ultra-high-sensitivity next-generation sequencing–based measurable residual disease (UHS-NGS MRD) in older patients with acute myeloid leukemia.

From: Ultra-high-sensitivity next-generation sequencing–based MRD predicts outcome in intensively treated older patients with acute myeloid leukemia: results from the ALFA-1200 cohort

Fig. 1: Prognostic impact of ultra-high-sensitivity next-generation sequencing–based measurable residual disease (UHS-NGS MRD) in older patients with acute myeloid leukemia.The alternative text for this image may have been generated using AI.

A Cumulative incidence of relapse (CIR) according to UHS-NGS-MRD status using a DTAI-excluded multi-target approach. B Relapse-free survival (RFS) according to UHS-NGS-MRD status using a DTAI-excluded multi-target approach. C Overall survival (OS) according to UHS-NGS-MRD status using a DTAI-excluded multi-target approach. D CIR according to the number of persistent MRG mutations among patients with exclusively MRG markers. E RFS according to the number of persistent MRG mutations among patients with exclusively MRG markers. F OS according to the number of persistent MRG mutations among patients with exclusively MRG markers. G CIR according to an integrated molecular MRD classification combining persistence of non-MRG mutations and MRG mutation burden. H RFS according to the integrated molecular MRD classification. I OS according to the integrated molecular MRD classification.

Back to article page